|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.000 CAD | 0.00% |
|
0.00% | +19.40% |
| Jan. 02 | InnoCan Pharma to List on NYSE American Next Week | MT |
| Jan. 02 | Innocan Pharma Corp Brief: Anticipates Listing on NYSE American Stock Exchange with Concurrent Offering | MT |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
Revenues | 8K | 196K | 2.56M | 13.66M | 29.44M | ||
Total Revenues | 8K | 196K | 2.56M | 13.66M | 29.44M | ||
Cost of Goods Sold, Total | 5K | 75K | 452K | 1.68M | 3.25M | ||
Gross Profit | 3K | 121K | 2.11M | 11.98M | 26.19M | ||
Selling General & Admin Expenses, Total | 2.98M | 6.2M | 6.85M | 13.98M | 25.88M | ||
R&D Expenses | 1.74M | 1.4M | 1.53M | 1.8M | 1.55M | ||
Other Operating Expenses, Total | 4.73M | 7.6M | 8.37M | 15.78M | 27.43M | ||
Operating Income | -4.72M | -7.48M | -6.27M | -3.8M | -1.25M | ||
Interest Expense, Total | - | -13K | -2K | - | -7K | ||
Interest And Investment Income | 21K | - | - | - | - | ||
Net Interest Expenses | 21K | -13K | -2K | - | -7K | ||
Currency Exchange Gains (Loss) | - | -290K | -415K | 4K | -42K | ||
Other Non Operating Income (Expenses) | -5.25M | -2.31M | 2.8M | -235K | 2.22M | ||
EBT, Excl. Unusual Items | -9.95M | -10.09M | -3.89M | -4.03M | 919K | ||
EBT, Incl. Unusual Items | -9.95M | -10.09M | -3.89M | -4.03M | 919K | ||
Income Tax Expense | - | - | 1K | 214K | 1.18M | ||
Earnings From Continuing Operations | -9.95M | -10.09M | -3.89M | -4.25M | -262K | ||
Net Income to Company | -9.95M | -10.09M | -3.89M | -4.25M | -262K | ||
Minority Interest | - | 44K | 125K | -452K | -1.57M | ||
Net Income - (IS) | -9.95M | -10.05M | -3.76M | -4.7M | -1.83M | ||
Net Income to Common Incl Extra Items | -9.95M | -10.05M | -3.76M | -4.7M | -1.83M | ||
Net Income to Common Excl. Extra Items | -9.95M | -10.05M | -3.76M | -4.7M | -1.83M | ||
Per Share Items | |||||||
Net EPS - Basic | -3.99 | -2.91 | -0.98 | -1.19 | -0.43 | ||
Basic EPS - Continuing Operations | -3.99 | -2.91 | -0.98 | -1.19 | -0.43 | ||
Basic Weighted Average Shares Outstanding | 2.49M | 3.45M | 3.83M | 3.95M | 4.31M | ||
Net EPS - Diluted | -3.99 | -2.91 | -0.98 | -1.19 | -0.43 | ||
Diluted EPS - Continuing Operations | -3.99 | -2.91 | -0.98 | -1.19 | -0.43 | ||
Diluted Weighted Average Shares Outstanding | 2.49M | 3.45M | 3.83M | 3.95M | 4.31M | ||
Normalized Basic EPS | -2.5 | -1.81 | -0.6 | -0.75 | -0.23 | ||
Normalized Diluted EPS | -2.5 | -1.81 | -0.6 | -0.75 | -0.23 | ||
Supplemental Items | |||||||
EBITDA | -4.68M | -7.44M | -6.23M | -3.77M | -1.21M | ||
EBITA | -4.72M | -7.48M | -6.27M | -3.8M | -1.25M | ||
EBIT | -4.72M | -7.48M | -6.27M | -3.8M | -1.25M | ||
Effective Tax Rate - (Ratio) | - | - | -0.03 | -5.3 | 128.51 | ||
Normalized Net Income | -6.22M | -6.26M | -2.3M | -2.97M | -998K | ||
Interest on Long-Term Debt | - | - | - | - | - | ||
Supplemental Operating Expense Items | |||||||
Selling and Marketing Expenses | 914K | 2.5M | 3.49M | 10.91M | 21.77M | ||
General and Administrative Expenses | 2.07M | 3.71M | 3.36M | 3.08M | 4.12M | ||
Research And Development Expense From Footnotes | 1.74M | 1.4M | 1.53M | 1.8M | 1.55M | ||
Stock-Based Comp., R&D Exp. (Total) | 64K | 109K | 120K | 102K | 250K | ||
Stock-Based Comp., S&M Exp. (Total) | 121K | 490K | 223K | 96K | 396K | ||
Stock-Based Comp., G&A Exp. (Total) | 343K | 1.56M | 624K | 656K | 1.41M | ||
Stock-Based Comp., Other (Total) | - | -1K | - | - | - | ||
Total Stock-Based Compensation | 528K | 2.16M | 967K | 854K | 2.06M |
- Stock Market
- Equities
- INNO Stock
- Financials InnoCan Pharma Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















